Latest Insider Transactions at Zentalis Pharmaceuticals, Inc. (ZNTL)
This section provides a real-time view of insider transactions for Zentalis Pharmaceuticals, Inc. (ZNTL). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Zentalis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Zentalis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
4,733
-0.19%
|
$236,650
$50.46 P/Share
|
|
Feb 14
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
7,188
-0.6%
|
$359,400
$50.36 P/Share
|
|
Feb 14
2022
|
Alexis Pinto Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
691
-1.51%
|
$34,550
$50.46 P/Share
|
|
Feb 14
2022
|
Dimitris Voliotis SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
601
-1.82%
|
$30,050
$50.46 P/Share
|
|
Feb 14
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,688
-0.2%
|
$234,400
$50.4 P/Share
|
|
Feb 10
2022
|
Anthony Y Sun President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,431
+3.96%
|
-
|
|
Feb 10
2022
|
Cam Gallagher President, Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
15,798
+1.94%
|
-
|
|
Feb 10
2022
|
Epperly Melissa B, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,405
+5.8%
|
-
|
|
Feb 10
2022
|
Alexis Pinto Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,405
+41.7%
|
-
|
|
Feb 10
2022
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Grant, award, or other acquisition
|
Direct |
10,329
+38.39%
|
-
|
|
Feb 10
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.42%
|
$530,000
$53.63 P/Share
|
|
Feb 10
2022
|
Kevin D. Bunker Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,481
+2.84%
|
-
|
|
Feb 07
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.84%
|
$530,000
$53.54 P/Share
|
|
Feb 02
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.44%
|
$607,318
$58.08 P/Share
|
|
Feb 01
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.22%
|
$607,318
$58.09 P/Share
|
|
Jan 20
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.78%
|
$600,000
$60.22 P/Share
|
|
Jan 20
2022
|
Dimitris Voliotis SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
10,000
-36.15%
|
$600,000
$60.87 P/Share
|
|
Jan 20
2022
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.1%
|
$180,000
$18.0 P/Share
|
|
Jan 19
2022
|
Dimitris Voliotis SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
10,000
-25.1%
|
$610,000
$61.43 P/Share
|
|
Jan 19
2022
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.1%
|
$180,000
$18.0 P/Share
|
|
Jan 18
2022
|
Dimitris Voliotis SVP, Clinical Development |
SELL
Open market or private sale
|
Direct |
10,000
-21.19%
|
$630,000
$63.05 P/Share
|
|
Jan 18
2022
|
Dimitris Voliotis SVP, Clinical Development |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.1%
|
$180,000
$18.0 P/Share
|
|
Jan 18
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.62%
|
$630,000
$63.05 P/Share
|
|
Jan 10
2022
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.27%
|
$680,000
$68.58 P/Share
|
|
Jan 05
2022
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.35%
|
$760,000
$76.07 P/Share
|
|
Jan 04
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.22%
|
$827,209
$79.11 P/Share
|
|
Jan 03
2022
|
Kimberly Blackwell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-16.67%
|
$83,000
$83.74 P/Share
|
|
Jan 03
2022
|
Kimberly Blackwell Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.29%
|
$47,000
$47.8 P/Share
|
|
Jan 03
2022
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.14%
|
$837,680
$80.84 P/Share
|
|
Dec 30
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
8,750
-1.16%
|
-
|
|
Dec 20
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.21%
|
$790,000
$79.13 P/Share
|
|
Dec 16
2021
|
Anthony Y Sun President & CEO |
SELL
Bona fide gift
|
Direct |
15,000
-1.22%
|
-
|
|
Dec 15
2021
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.3%
|
$750,000
$75.2 P/Share
|
|
Dec 10
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-1.15%
|
$710,000
$71.83 P/Share
|
|
Dec 06
2021
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-2.29%
|
$710,000
$71.33 P/Share
|
|
Dec 02
2021
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.13%
|
$785,325
$75.89 P/Share
|
|
Dec 01
2021
|
Kimberly Blackwell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-16.67%
|
$81,000
$81.84 P/Share
|
|
Dec 01
2021
|
Kimberly Blackwell Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.29%
|
$47,000
$47.8 P/Share
|
|
Dec 01
2021
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.12%
|
$806,267
$77.53 P/Share
|
|
Nov 26
2021
|
Anthony Y Sun President & CEO |
BUY
Bona fide gift
|
Indirect |
125,000
+50.0%
|
-
|
|
Nov 26
2021
|
Anthony Y Sun President & CEO |
SELL
Bona fide gift
|
Direct |
125,000
-10.0%
|
-
|
|
Nov 22
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-4.35%
|
$750,000
$75.99 P/Share
|
|
Nov 15
2021
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.75%
|
$750,000
$75.82 P/Share
|
|
Nov 10
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
10,000
-4.17%
|
$780,000
$78.15 P/Share
|
|
Nov 09
2021
|
Kevin D. Bunker Chief Scientific Officer |
BUY
Bona fide gift
|
Indirect |
240,000
+50.0%
|
-
|
|
Nov 09
2021
|
Kevin D. Bunker Chief Scientific Officer |
SELL
Bona fide gift
|
Direct |
240,000
-24.12%
|
-
|
|
Nov 05
2021
|
Cam Gallagher President, Interim CFO |
SELL
Open market or private sale
|
Direct |
10,000
-0.73%
|
$820,000
$82.95 P/Share
|
|
Nov 02
2021
|
Anthony Y Sun President & CEO |
SELL
Open market or private sale
|
Direct |
10,471
-0.28%
|
$837,680
$80.27 P/Share
|
|
Nov 01
2021
|
Kimberly Blackwell Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,000
-16.67%
|
$80,000
$80.46 P/Share
|
|
Nov 01
2021
|
Kimberly Blackwell Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+14.29%
|
$47,000
$47.8 P/Share
|